Krystal Biotech (KRYS)

• Market cap: $4.69B
• 1 day: -3.64%
• 5 days: -20.66%
• 1 month: -21.40%
• 3 months: -14.46%
• 6 months: -32.52%
• Year to date: -15.54%
• 1 year: -16.73%
• 5 years: 120.30%
• 10 years: 1,142.29%
• Sector: Healthcare
• Industry: Biotechnology

About: Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

Employees: 275

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

72% more call options, than puts

Call options by funds: $63.3M | Put options by funds: $36.8M

0% more funds holding in top 10

Funds holding in top 10: 6 [Q3] → 6 (+0) [Q4]

2% less repeat investments, than reductions

Existing positions increased: 94 | Existing positions reduced: 96

1.04% less ownership

Funds ownership: 97.58% [Q3] → 96.55% (-1.04%) [Q4]

6% less funds holding

Funds holding: 279 [Q3] → 262 (-17) [Q4]

15% less capital invested

Capital invested by funds: $5.1B [Q3] → $4.35B (-$753M) [Q4]

24% less first-time investments, than exits

New positions opened: 38 | Existing positions closed: 50

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $189 43% upside
• Avg. target: $221 67% upside
• High target: $245 85% upside

6 analyst ratings

• positive: 5 83%
• neutral: 1 17%
• negative: 0 0%

Guggenheim Debjit Chattopadhyay 30% 1-year accuracy 8 / 27 met price target	43% upside $189	Buy Maintained	7 May 2025
Chardan Capital Geulah Livshits 12% 1-year accuracy 8 / 68 met price target	66% upside $219	Buy Maintained	7 May 2025
HC Wainwright & Co. Joseph Pantginis 18% 1-year accuracy 70 / 396 met price target	82% upside $240	Buy Reiterated	6 May 2025
Jefferies Roger Song 28% 1-year accuracy 5 / 18 met price target	85% upside $245	Buy Initiated	5 Mar 2025
Citigroup Yigal Nochomovitz 11% 1-year accuracy 4 / 36 met price target	63% upside $215	Neutral Maintained	20 Feb 2025